<SEC-DOCUMENT>0001193125-11-214250.txt : 20110808
<SEC-HEADER>0001193125-11-214250.hdr.sgml : 20110808
<ACCEPTANCE-DATETIME>20110808161531
ACCESSION NUMBER:		0001193125-11-214250
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110808
DATE AS OF CHANGE:		20110808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		111017385

	BUSINESS ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;8, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Arrowhead Research Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21898
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46-0408024</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>225 South Lake Avenue, Suite 300, Pasadena, CA 91101 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (626)&nbsp;304-3400 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02 Results of Operations and Financial Condition </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;8, 2011, Arrowhead Research Corporation announced and commented on its first quarter financial results for the quarter ended June&nbsp;30,
2011. A copy of the press release is furnished herewith as Exhibit&nbsp;99.1 and incorporated by reference herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In accordance with
General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.
Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated August 8, 2011.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:&nbsp;&nbsp;&nbsp;&nbsp; August&nbsp;8, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARROWHEAD RESEARCH CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Kenneth Myszkowski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kenneth Myszkowski</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</FONT></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g218263g82p02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;8, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact:</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Brandi Floberg</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Piacente Group, Inc.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">212-481-2050</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ir@arrowres.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARROWHEAD REPORTS FISCAL 2011 THIRD QUARTER FINANCIAL RESULTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Calando Completes Phase 1 Trial; Initiates Phase 1b </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PASADENA, Calif. &#150; August&nbsp;8, 2011 &#150; Arrowhead Research Corporation (NASDAQ: ARWR)</B>, a nanomedicine company with development programs in oncology, obesity, and regenerative medicine,
today announced financial results for its fiscal 2011 third quarter ended June&nbsp;30, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;In recent months our focus has been on
advancing the platform technologies of Calando Pharmaceuticals and Ablaris Therapeutics into the clinic. These innovative nanotechnologies have created drug candidates addressing high unmet clinical needs in cancer and obesity,&#148; said
Christopher Anzalone, Chief Executive Officer of Arrowhead. &#147;We are pleased to announce that we have completed enrollment for the Calando Phase 1 trial, marking a significant milestone for us. Consistent with our previously reported interim
data from the trial, we have a system that is well tolerated in humans, has the ability to shuttle siRNA into target cells to silence disease-related genes, and can potentially be used to create a virtually limitless number of customized RNAi-based
therapies. As I have said in the past, we firmly believe that our RONDEL&#153; delivery system is capable of solving the primary challenge of RNAi today: safe and effective systemic siRNA delivery. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;While we have met our goals for Phase 1 and believe our data are strong, we will expand into a short Phase 1b study because we may be able to
increase the therapeutic window for CALAA-01 even further by simply changing the dosing schedule. We believe that the dose-limiting effects we began to see in the Phase 1 trial may not have been related to the RONDEL system, but rather to the naked
siRNA inside. This has enormous implications for future clinical </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
candidates because we can eliminate responses associated with naked siRNA using established chemical modifications and thereby likely substantially expand the therapeutic window. This is
important for CALAA-01 as well because we believe that pre-treating patients with an initial desensitizing lower dose of CALAA-01 will enable us to increase beyond the maximum tolerated dose we established in the Phase 1 trial. What is important to
us is that RONDEL has been shown to be safe and effective and that we still may have room to increase the dose. We are confident that additional data that further demonstrates the safety profile of CALAA-01 and RONDEL will add to the value of our
RNAi clinical assets. We are continuing to explore third party collaborations and believe that data from the Phase 1b study will be helpful, but not necessary, to initiating partnerships.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Anzalone continued, &#147;Our development program within Ablaris remains on track to bring its first anti-obesity compound into the clinic by
the end of the year. During the third quarter, MD Anderson commenced studies that the FDA indicated were necessary to begin clinical trials. We are excited about the potential for this drug candidate and its addressable market, and we remind
investors that the Phase 1 trial will be conducted at no additional direct cost to Arrowhead. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Heading into our fiscal fourth quarter,
Arrowhead is focused on obtaining additional data for the Calando trial and partnering this program, as well advancing the Ablaris and Nanotope platforms. We believe that nanomedicine is going to transform the pharmaceutical and biotech industries,
and we are confident that Arrowhead is at the forefront of that movement. We have a number of programs with attractive addressable market opportunities that are based on world-class technology, putting us in a strong position for growth,&#148;
concluded Dr.&nbsp;Anzalone. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THIRD QUARTER FISCAL 2011 AND RECENT COMPANY HIGHLIGHTS </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#149;</B></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>Business highlights: </B></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expanded Calando Scientific Advisory Board with the appointment of Timothy J. Triche, M.D., Ph.D. to guide future development of CALAA-01, contribute
to partnering activities, initiate new clinical candidates, and expand the RONDELdelivery system. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presented updates on RNAi research at two nanomedicine-focused events in London. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Received notification from the NASDAQ Stock Market providing for an additional 180-day grace period, until December&nbsp;5, 2011, to regain compliance
with NASDAQ&#146;s $1.00 minimum bid requirement. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SELECTED FINANCIAL RESULTS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No revenue was recorded for the three months ended June&nbsp;30, 2011 and 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating
expenses for the quarter ended June&nbsp;30, 2011 were $1.8 million, compared with $1.4 million for the quarter ended June&nbsp;30, 2010. The increase in operating expenses was primarily due to increased outside lab services and contract services to
support enrollment in Calando&#146;s clinical trial and increased costs related to foreign patent filings and attorney fees associated with Calando&#146;s intellectual property portfolio. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Loss from continuing operations attributable to Arrowhead for the fiscal 2011 third quarter was $1.9 million, or ($0.03) per share, compared with income of $84 thousand, or $0.00 per share in the
comparable period in fiscal 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total net loss attributable to Arrowhead for the quarter ended June&nbsp;30, 2011, which includes
discontinued operations, was $1.8 million, or ($0.03) per share based on 71.8&nbsp;million weighted average shares outstanding. This compares with a total net loss attributable to Arrowhead of $371 thousand, or ($0.01) per share based on
64.6&nbsp;million weighted average shares outstanding, for the quarter ended June&nbsp;30, 2010. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFERENCE CALL </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management will host a conference call today, Monday, August&nbsp;8, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the
conference call, please dial 1-800-860-2442 (toll free from the U.S. and Canada), or 412-858-4600 (for international callers). Investors may also access a live audio webcast of this conference call on the Company's website at
<U>www.arrowheadresearch.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A replay of the webcast will be available approximately two hours after the conclusion of the call. The
webcast archive will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until Monday, August&nbsp;15, 2011. The audio replay can be accessed by
dialing 877-344-7529 (toll free from the U.S. and Canada), or 412-317-0088 (for international callers) and entering passcode 10002293. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ABOUT ARROWHEAD RESEARCH CORPORATION </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead
addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative
medicine company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For more information please visit http://www.arrowheadresearch.com. To be added to the Company&#146;s email list to receive
news directly, please send an email to ir@arrowres.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement under the Private Securities Litigation Reform Act:
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as
a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our
markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our
business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g218263g82p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g218263g82p02.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`40"G`P$1``(1`0,1`?_$`+$``0``!@,!`0``````
M```````!!@<("0H"`P4$"P$!``$%`0$!``````````````0!`@4&!P,("1``
M``<``@$"`@4)!08'`````0(#!`4&!P`($1()(1,Q02(4%?!18:&Q<B,6%W&!
M,D+"T>&R,R0*TR;&UC=7EQ$``0,#`P(#!@0%`P4!`````0(#!``1!2$2!C$3
M05$B87&!,A0'L<$C%?"1H4(68I+2\5)R,S0E_]H`#`,!``(1`Q$`/P#?XXI3
MBE.*4XI3BE.*4XI3BE.*51;<]SI&!TPUONLO"QY7+U*+@X^7GHRN?CDJKY4%
M@TDI=5)BFLDS347,)S`'H3'ZQ`!CR)+49HN+('E<VN?*M2YES'%<)Q)RF4<:
M3N4$-H6XEH.+/]H6H$`VN=1;2K*LY]QFA2EL:Q%VN.9-H>:DD6;.1CKO2VYH
M,')Q(@#U!O;9MW,%45$B?\%)(P&-ZO'I\^($?)E;FQWMA)-@0M/X7KCG&_OO
MCI&4$;.28"8;SFT*3(9_2OH`H)4I3ES87`'F=*R=E.!P*8H@8A@`Q3%'R!BB
M'D#`(?#TB`_3]?,QI:]?1P5<`BQ!\C?3S]U<^4JZG%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*^=TZ;LF[AVZ<(M6K5%5PZ<N%2(MVS=!,RJRZZ
MRABII(HI%$QS&$"E*`B/PY0D#56@`O>K%K2VA3BR$H2+DGH`.I^'\JP#=I-]
MTG4]3DG5*=032B5L5X&H2-&]QC,\D;6>,3<'7-9IFI,1D_N\I(+*&*055C*D
M:D2*8"F]0<UJ9->>=LSVPT.A[Z4W'G;P-?(?W(F<DY5R`O8]SMXE@%MHQL\W
M##B;D]QQE*%V6HW`))(%A;K5O"U@W-N1L=S)61!-XW!VS.O[L5&1*[:&550*
MZ:F4CB@NV%=!0@*$\E$Y#!Y\@/B&7Y0MNV65J+RDV_"N?KXURML)+C\Q"5#=
M<\H0";W`(/9U!(/F`1<:BLS'1K<Y71*&%%OBU297NDID:L&<;V"I.^62S5-!
M%`B%HG)^M."2"D@W>+BV=*.6R?J$4C`8PG'QL./E%YK8YM#R=+)6E=QYZ>'A
M7U7]JLYD)F#3B<V61E(H"$[9S<UQQH`6<=<0$J*[^E14D7T/6]7X<R-=4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2L8GN1]B[+F]-8Y#3<,NV
MVNM1B9)O=FE>9Z`QBH:CJE,R6;K6>C,%7K>5L#H#(%036(8&I%A/X`Y/5A\M
M*6TW].VVIPK&MMV@]X!K1^:Y*0S#_;8T54D/@AP`K2`@^&]&H)Z6OTK#)U_P
MNM;AK=.S-S[=#FB1$Z],I8;?9+CO\+&5NM,"@XFI,',P+%FN_2:E]#1N*@&7
M<J$)]`B(:S%@,R'TM")M03J255R#%<'Q61GHAKP:&6U:*7W'@$(\3=0U4.@'
MC68/N]TKQMWA$19J;UPKVF6+`J:W@Z=1T9VW5AT\SR.4(M)P[%Q4724A-2\<
MF!WC=-<%CKJBL`"*JWQV')XR*N,%)9"U-#0!6W2VO3K72>5<"P$K$H<:Q[3[
MT-H(;1=2/TQK:Z-21<G6^I/G6&O%M,G\$T2`U#,?;@N]9M$**Z)9"/E>Q#H[
MB)DDONTK'JLI%@O&OT7;,X^E-PF=(%2D.(>2@(:_$6(3P?9B+#@TON5T/AJ.
MGOKGF%@(X_DD93&X534I!^9+CY)2=%`BWJT)T-Q>U;7%"N##0*95[M&-):.8
M6B$CYIO'3L:]AYJ.!\W(JI'2T7((MGC&18+"9)9,Y`$%"#X\AX$=[0L.("P+
M7'3RKZ)C/IE,(D(!"%I!L00?:"#8@@Z'2IOY=4BG%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4JG6K:75LBHE@OEOG*W`1<,R.+9S:[+$5"&?3*Y3)0L*O
M89Q=O&1JLQ(BFW345-Z2B?R("`#RJ4E1VIU54:5):B,E]Y24H'0D@"_@+G36
MM1_0Y#MEI-[ME\DNW>$Q$A;YUW+FA*WW=J<1"11'2H)L(:'BX^THM6S*/:E3
M02*0GJ.!/4/DQA$<2YBI[CA<4MP$GH#8"N9OR)LB2I0DM[E*U`?2+>`%AH+?
MUK8H]O/KII.#8X=UM=TL%SUN^/"S-C_%+O+W:(K,6W^:C7Z[7W[]\[:K)D:'
M,Z<N42E^<NY$OQ(F0>28<949!2M96X3X_A6^86"_$BWE+*I"]3K>P\!?Q]_C
M5_@_1\.3*S-:RW?[K%V/RG9IBW9[V+;TK&=%?JRU61TGLZZS-.%L3D%7=@IT
M.A9+"V3?,H\__4M?DF-\MJN"8A_"$1Q;N,DONE3"U6/]*T#-PIL225LO%$99
MNF[NVRO'0Z6'O\:K?[8&W:'F=NF\AW3?\,O]9OSQL[H;QGV<I.DW./OBQD&`
M5QA'#.O)J1C[0@!/EI)"?Y+M$/27^,;DN)`EQ0KO$J2:E<?R"F5F++=;4VO5
M![J5$GQ%KWUK/T`A_NY)K=?94>*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5
M`1\?E^7U\4\;5J;^\WKEI[5Z/"8QDW8;J%#XQDKM=:>96KM9EE4GK)JZ8KQT
ML,[7'TF#R/1HR8*L&Z*_DWWI1PIX`!)XWK`X?ML&3+C25K6/3M:41MT(-P/&
MN&\]SW[I-3C\?,QR83"O5ODH0HKU!].ORVM\2:LI]O+K=AE*[*572NX7:KIC
M&9GFPIVZ$KD%V4S*YKW.],'*1ZTQE&C"1%)K`PKHOW]Q\T1!PH@DB!1*900F
MY6'),0MXZ)++RC8W;78#W6K`<8&)9R:)&?R..3!:]02B2A94OP!&GI'S>TZ>
M-;E&0=H.N>_O9J,P_<,NUN0K;5F^L#//KI`VMS"LY!99!BZDT89Z[.R0=KMU
M")F4`H',00#SX'FB2L=/@!/UK3C>Z]MR2+VZUWK&9_"YDJ3BI3$A2`"KMK"K
M`Z"]B;7-5V$0`!$?@`!Y$?T!R$=!>LN2!J>E8@>[VX^V_P!NL`T3"+9W'ZSQ
M$^Y2<N:?.OM8I?WJCZ1`"X+!3!B?BHN$BLY$#-GR8!ZE&BJR?CR;X;#$PV=8
M?2\(D@MZ7';400?AKIK7/>0Y_AF7QCN.=R4-+UCM/<1=*A\=-18^RM09CU?T
MJ(D&<G%=E^C[&4B7[=_&2T=W+R1LY9R$>Y(Y8R3!;\337070<HD62-X*<A@`
M?@(<WDPHZA9R++(\?TEVMXZ=*X>AN0A8+<[%`BUB)2.H^4V\/;6\E[?_`&8'
ML;@M;7MM]QRY;71XR-KVP)XUJ-3U&!3FR$70C+(K(U1XY;QH7-DQ%\#=0I!1
M6%5,ODI`'G.\OC7<=+*2VZB,K5&]!2?=KUM7T3Q//-9O%H4X]&<R*``Z&74N
M`'H#<:V5UU\:OF\_JYBJVFG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2J>ZU"6
MFRY9I5=HTH$'=9_/[G"4^:,J9$L1:96N2+&O2AEB_:2*PEET5?4'Q+Z///>(
MXRS,:>D`&.EQ)4/-(4"1\14/(LOR,<_'BJVR5LK2@^2E)(2?@2*_**T7JOV\
MS&ZV&BZ+URW./N=>DW;&>(;-;G-(N7Z:Z@+R#2<CHA]&S;*05\JI/&ZZR+@A
MP.4X@/GGU]$R^$E1D2(\J.65)TNI((]EB01;W5\`Y'@>?BS'&I$5X.!1OZ5'
M^HT/OO4E_P!$^PW_`-`;A_\`D>@#_P"G>2/KL8>DF-_O1_RJ%_A>9.OTSW^Q
M5;5G_:QT32:AKO<!:]YS?*.W>YSDZ4:XN-,LE62D5D+/;SN$62T[&L4WBK<B
MA1.5,3"4#`(@`"'.0?=R3#>APOIWD.*#BPH!:56Z6T220/?7T%]AL)-P\Z>J
M4RXWO9;`W`@&RC>UP-=:W/%/^6?Z_L&^`?7\!YQ'I7TFN^PVZV-?DBZ%C'8)
M;0;^JA@NV+H*7NXJ(K)9-?U$E45+))F2524)71(HFH00$#%'P(#\!Y]B09^+
M1$;;$B.!VD7NM-[D=/FK\_<KP[+NY!]Q,9\I4ZH@[%:Z^)J4!Q3L*'TX#N'Q
M^'_Q'H/_`+=Y),_%C4R8]O\`S3_RK&_X5F;_`/S/?[%5M`_]LEUD[85#LAJV
MX6_/-!R["ELBD:/(K7JOS%3;Z#<GEEKTG7VD'$3C9@[E?Y8:L'BZKXB)DFWS
MOD@?U+B7G)_NME,/(QS4%IQI[(]X*]!!V(VD$D@D"^@M>]=W^QW%,[BLR_E)
M#;C&.5'*#N24[U%22+7U.VQ/D/C6[4'.$IO;6OI_2]ZCRM*<4IQ2G%*<4IQ2
MH>?T?E\/]O*7UM5+T`0'^_B_G5?9XU'E:4XI3BE.*5Q']OU?H_./+57!N.G]
M*'IXT#R(?3^KE4D$=/RJE[ZBH^!_/^KEVE5M[_X^%0\#^?Z^6$$FY_C^!5`+
M5$?`@/\`9^W@J&HZG\:K7'R(?2/";$^-^O\`TI4?C^?]7*D^%JI[K_Q\*B`_
M3^C@7MK5:CRM*<4IQ2G%*<4J'G]`\H387\:>-//&X=?[?.E_YUA%][;NNZZZ
M9-D77S/]HBL&V?M]J5=SJ+V%_9&U6_HAE$?+QCS5MC6FUG+<(D(2)528-E1,
M0QEWPBF;UI\WK@F`3E9[N0E1S)@0FBLM`7+J[$(;^)-SY!/0WK0N>9XXN&SC
MX\A$:;,<".XI5@T@'U+.H/D-"#J==*M+Z`^ZQ,5;I+WUA+WIT-VYVWVVOZES
ML5HG\\)O6_9C%V;F7ELUT`+DT2FW+@7:;52/?.P1<G;>&P*`90X^<OR'AZ7,
MY`<CLF#!R?;&PI_]+M@%I*;VZFZ1<7%^EJPO'.8J8P,]+[HF3L;O4%!5^ZU<
M[2%V)M[3<@%-ZJY)^\#VRS_K'L'9C7^AL57*15NL..=F<EN=6V"=LF8Z,SUJ
MU5J$)FLO;WN6P2E:T*OP]D*_<M4&[\I`1,01])BJ<AIX;B'\JSBH>1WO+E.L
M.`M`+06P3O"=YNE1%@;CXU-'-LPWBG,M,QX1'^G:=;(<)2H.%`VE6S10W=!?
MY3<#2_O7/W@>PV#9E?K-V3Z*2-7N3VT=>:+U?;Y]ISRS9AV1NO8J'=3$)7H;
M2;'G]33@EZ4V;@,V?[DZ!%011(`G`!&QCAF.R,MIG&3PXP4/+>*F]JVDLG4[
M`LWWZ[=17J]S7)08SKF2QZD2+M!D)7N0\IT$@!92+;?[M#Y4OGNK=Q,"N5SP
M;L-TJSZ,[&R/7'0>R77N$R_=7]VSS78K)T5)G0\YDYM>@1UAJEYB*Q'OG#8X
M,7C1ZNW*F42E5(<:,<2PT]AN?CIZU0/J4,.E;6Q:%.:(4!O*5))L/F!%_95S
M_+\UCY*X&3@(1-^G+S>QW>E24W*DW";A02DG06)%O$&O*MWORT-AJ/2.NT?)
M!N>3]DL\PS0=RUA.U+-6/6=MV'MIJ#GT98&2->=MI)Z%O9ND'0.'+`2II%,4
M!$W@/5G[?R519SC[W;F17'$M-E/_`+^TG>HI.ZX&VQ%@;WKQ>^X;*),)#3)7
M%D-MJ=7<W8+BMME:6.TWW7(T%6H=V?<^[*[$O29;JO#NJ'2LT]W'-.I%!LL/
MK<S6([MDY@(B85O]5NCEC6OD5K+GUF,T8*JD-+$63.*HI^4Q3',8'BF+B=Q.
M84EUU[#KD*!:"C'OJDBYU78'3TD$'PM6&Y%RW+3"TO#I4VVWEDL)(<*0_8'<
MDZ#T'TFX*A8U>-*>]59<):=YJ[W%ZOH9EK72G/\`*M(>57*-;::E5]-BMHEH
MNNT.,A+9(5"GKP<DXFYUD1R9RQ4(B@JHIZ?4B*9\(WP=.1./<PLDO19SBV]R
MV^V4%L$JNG<JXL#;74_SK/.<Y>QJ)R,Y&2S*AH0JR'-Z5AS:!KM&VQ6-QL=/
M"^E?/UT]XRZ;NWT%VX9=!*\:K8/<=ACX=AW9FYN7AGL`VB'+&+U%5W@\%"4J
MM-1E/DS,LBZ?_AZX%*F@X]?PIE.&-8XMI09R]\A+=_I@`021='ZI*CI<)L+^
M8KSQG.9.0[BE)@-I0PIRWU))!`!`7^F`D&_6YL?`U(&.^_(YLO9;KU@^@T'K
M18X3L/=39W%7;J[V>FMH=4:R.$`4AWMQKMCQK./_`"W*N#E2*Y:.EA+Y,<`-
MZ/2:3/X`(^*DY%AR2%QT!>UYD-A2;V-E!Q6H\K5'Q_W#7(R;$&2U%+;ZRG<R
M^7"DBUK@MIO>_@>FM6V]UO=<[D]CO;H[1=C^I^%*89UOJ=J-1ZUVE6[%&K6Z
MG/5-5K-8D;-1\QK=,6409S,BJ$>J1><04(U<KB`J?*$!R6&X=@\;R*+C,Q(+
M^56WO+`:NUZD*4`7"K^T"_RZFW2L7G>89W)<<DY3$1DL8U"TI2\7K.&RD@V0
M$W%[V^86UZVK+O[B>H:1GGM$[OK5$O5GJ&H0?6&!LT+H$!,.XNU15B7CJRHO
M.,YILH1XVD55'*AC+%,!Q$YOC\>:;Q>)%D\PC1)#:7(BI)!01=)3KH0=+:5N
MO(I<ECASLQIQ:)*8S:@M)(5?TWL0003>VGG6L7.]IMM:Y5UAC^M/:KWDIGOY
MMQ<B7S:C=AOE-.LFI69ZA7I+2TX->]1L?'6J@)-7;E5BLDLY!1J9`Q_L*";G
M64X:']=*7EXF#_QQCNAQ;`'?0D%6R^PW2J]@;CS%<D_>9AB1$XV9FSR%X,A*
M'KAA:E6*B+_.#?0@VZ7T-JS4=@??(5R7LCH_5JL4_KFUMN#P50:ZUH?8[L5)
M852IO0YROQTM,5?+H^'RS2IJ?;U]1YX<.7)6I"_04!#TF/H6,X%]7B6LNXX_
MV7U*[:&6>ZH(22-RR5H`Z6L+FM\R/W`5"RKN)91'[T=*0ZMYTMI*R!=+8"%7
MM<^736O(V/WT;5G>Q1V.1N6]:H$4,)R/7Y35=I[+VW.\AO+W4:S&V0\;AMFB
ML)MKF_UV"3D/1^).4(TS@J9C?(2$HEY?`X&B7`_<%.R5)+SB`AM@+6D-FUW0
M7$["=--;7ZFJ3_N#(BS!##,5)["'"MQY2$**@#Z"&SN38Z*-KV.E37O'OD1N
M+0?4ZL(U7KG:=A[-9]9-1>VA+LR=AU-H--@9Z9@FCP-S0S.5F[2_GG<*LW1:
MHUYNJB\3.DJ!1`//GC^!KG.S%J<?;BQ'4MA)9O(6HV)_2W`)V@WU7J.E>N3^
MX/[>W$;0W'<ER6RLGO690D;K?J;2224GHG3QZU,=E]WJYPG73*MN1<^W=]^T
M"_Z337C>6[MV>-HZJ-*+`BP-0[*3K\ZL-VG/7)K!,-2PS9&*\(?QUA7\$CL<
M/;=RKN.4,CM;;2JXC`K!-SZT]VR1H-IW$G732O9[FTAK%-9'_P#/W.+4D@R"
M$#;;Y5=LE1!)N-N@L;ZFU(*_[_3N8ZJ=X]L+@E$F-"Z3V#(XZ2AZ'M3JWY!J
M$+KUG3KL3/4_2#YY"32!(P4US+HKPOJ$Y"%`0\G]$YW[>]O*X^$9"TQIZ%G<
MINRT%"2HI*-Y!)M;YJQ[?W*"\3.G&.@R82FP0APJ;<#BP@%*]B3U_P!)]]5>
MOON[]B^OU`O;SLCT/E:WISO7<)QCK1$4/4'$[EG9.V;Q"/YB.&M:A9Z!52Q3
M&E`R(E+J#'N?0X7(D4`$#&")&X=C<D^W^V9!*H88==?4M%EL):(!W-A1)W7&
MW45.?YMD<>PO]SQY1++C:&`E9+;RG`2`'"@6(MKH>O6J1^YUV:]RBB]!-5OV
MAYI3.HMTB-0ZUL,VLN`]EIV_62PK6;4F49<*O8I%'.J*-7B58TZ#=55%5Z1T
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M<O=U2T;DN+5:P"E!7R@6L`!T%9I_C6-EYDYN8%//]KMI0NRFTI_TH(ZWN;F^
MJC[+42V?V=>HNMZ9<=0@V]PPJ1TCKO<NL6CUG!5*50*/><VNGW@[U6?JX4F3
M9*6>-<*I*M'R0I"11HW%0B@)``S(',LU`BMQ+MO-M20^@NA2U)<`MH=PT(O<
M&_4V(J#D.%8>=)<DHWL*=CEE8:VI2I!).J=I%_QL+@V%5\U#H5CNM=&TN@%D
MF[^VQA+,:'E!9N)F8AMH(UO/#5\\(Y&:<P#R'&7<#6T/O*GX?\M0#']*9/(>
M(,3/S8F>_P`A0ELS>ZIRQ!V;EWOH"#;U&WJJ>_QR%(P*./*4X(2$(2""-UD6
M*=2"/`7TJ8.Q?2+"^TW7*+ZQZ['V&1HU=2I:]3GX2=5@+]3K)GS9!M4[M5K.
MQ0`T3;(LB(^%RHF2."JA#)"F<2<\L9FYV(R1RL,I[ZMP4DBZ5)7?<DCQ!!\_
M+6O;*8&!E\8,5+"NRD)VJ!LM)2+)4#Y^>EC5&>OGMF97BNV'[(WK7>P?:?=6
MM$?9A5M#[+WYA>'=$SZ44$\M7*?$1%=K<)&A-@<Y7SI1!9TY*HH`G`%5/7-R
M/*)<Z$,8PS'B0-X6I#"-@4L="HDJ)MX"X`L/*H.,XI#@3?W&0])ES@WL"WE[
MBE!%B```/$BY!.I\S>B.=>QKTAS'$>UN!5]+37--[<OH-S='\O:(1[9*(UJ,
MV]LM&A\KDRU9%*L1=)L$@H\CB+HO3D6]/K,<`\<GR.=Y^3.B9!PM=^&%!%@H
M!6X;5%8W'<5#0VM[*QT?[?X&)!EP6POL2]NZ^TE(224[/3;0G^X&_C52HOVD
M>KD)@?4[KM#R6FQU+Z?;I`]B*#)H6*!_FJW:7!3<S8#2.DRAZN9M8&TQ)3JP
MNRMV[)4Y"IE(H0"!R.OF&77D)61<[1?EQRRH%)*4H*0D!`W:$`:7)UN2#4H<
M+Q(@0\<A3J683X>3M4`5+!)]?IL0?$`#2UC4T:A[6_5S:=5[7ZIJ3.Z6]QW'
MR3/\;UBH/;$T:5)I7<S5C751F*<G&Q#.?@;5'2<0V=E=F?KE*Y2*8B90\@/A
M%Y5EH42)%C=M`A/+<;4$G=N6"%!1)L002.E[>-2)7%<5/DRI,GN*,MH(6G<+
M63L(*=+@@H21J0#?36J9,O:%R-UGVA8]H79'N!L6-Z+EK[))+,--U&H2E>B*
M\JXA7<-)P+V%S:!L*%DJB\`V-'N5WKA,OI$%DU@$0Y+7S/(?4-3&(T-F:T[W
M`M"%`J)N"%7600;FX`!\B*@,<)@M,+C.2IKL5;00$+6@I2!8@ILV#N20""21
MY@BO%KOLW9-&WOK3=;9V?[AZJUZE76NWG$J3H^@9O*4NN2=8:-(V-9*L8?)H
M.3=1@Q3%)JH3[V4YD">/6`B(\OD<TFNQ9$5N+":$M!2XI"%A9!-S8EPC4^RW
MLJL;A,-E^.^Y*F/)C*"D)6MLH&VU@0&PHCTCQO[:D_0?8FZQ7*JZ?EU8W/N%
MD&!:[9Y&XW3K=F>SQ;7#%K#*S;6ROG<33+32;2>(;KSK)!U]W1<@B15$GI*`
M%*4/5GGN5:>:E/,0GI[*`E+RVCW;`$:J2I-]"1TJ+)^WN,D-.Q69,YB`\K<6
M4.@M7N#<)4E5M0-+^'E61_>>KF>=ANKETZE7:2M3'-;UG3/,9>3KDA'L;>C`
M,D(]NBX82;V*D8U&4%.-3$RAV:B8B)OL!Y#QK>.RLK%Y1O+Q0@RVW-X"A=-]
M;W%P;:GQK:IN+CS\6<2\5_3*;2C2P59-B#<@C^W6XL:H?NWMM=?>P76G"^M%
MPD="AXOK:&6.,2U6HV"+AMEH$WD<3&0=;L4);E8!ZR;2SZ,BDTI#TL00<^?4
M"9#$2%.?`Y-D\=EG\LR&U.22X74*!+2^X25`HN+@$DC6X\^M8Z=Q?&SL3'Q+
MRG4MQ0@-.)*>XG8D)!"BD@$@"Y`&H!%B!5.--]I_&K[L-J[`5';.R^#;#I%=
MJL#KUPPZ_56KEUM>G1:$3$66Z5Z<H5HK86?[LW+\US'M6!5#>1$GQ'DJ'S#(
M0X*,<ZU&D1&EJ4VEU"CVRKJ$D+2=NO0DU$F\+Q\R:O(-/26)KB$I<4VI([E@
M!=04@C<;#46]EJ][1O;A=Z.XC!6[U=[ZG'1U&K%&/`4_4LYCH21;URO-Z\[L
M#YF^R.3,-CMA$#.I59(Z2*[Q4YTTDBB!`\HG)C#2H)@X]2E.*62I#E[J5NMH
MZ!9)Z:>\FKY?$Q,VA<^>E*6PW9*V[$`6N;MG4^/36J:C[*?3^*SSKG3<YFMM
MQ^U]6XBZ0>5;7FNA-(G74XO1IF2L%Z8V>9E:W-5VRL['-S#IRHBO%@F@HX.#
M<$BF$HS?\\SKDJ5)E=AY$M25.-K1=NZ``G:`0I-@`-%:CK>HYX%A$Q8\:.7V
M7(H4$.(799W7W;M"DWN2/3I?32OKMWL_9'=SXC9K!V1[=N=HZ]RN@O<S["IZ
M124M;C8C2BLRV"J/70YD>GOJ\@#/_I`&'*[0!94/GF`_@/)KF<]@R$-1H8B2
M0@*:V+V71T4/U-U_.ZB#Y4>X-`?0P7)4WZN.5;'=Z=]E7N#Z-I`N;>F^M2P?
MV2>N4IG?;>@779NS>BN.ZJV4.=KOMTN]&>7MRYQR8_&*DO`2,9FL5$QZAS@1
M!U\YDY!5NF4I0(8!,/JKG>7,F))::BM"$'`VA"%;?U4E*K@K).AT-Q8^=>8X
M!BC'EQWGI3OUI;[JE*3N/:5N18A``L>NFHJ^+M!TKPSM]AL9@6SQE@>U2O2=
M3L-0L-9L#JKWRDVZD$^76;E4K1&D!>(LD:0QR@J"9TSE5.4R8E'QS`XC-3L)
M..0@E/=4DI4%#<A25&Y2I/B#X]#[:V'+8*!FH`QTT*[*2"DI.U:5)%@I*O`@
M$^8\Q5J-K]I>C:5CMYPW9NV_=O<:/=I[+;&F&M:[5+9*T^3R>T_S9#*T]\?-
MV@,/QQZ1-&5,X(Z4=-T2`4R9P]8Y9KE\J+/;GP8D".ZA*Q^FVI-PM.T[O7<V
M'34`7-89?#8[\-<&;-GR&%J0?U7$K*2@W&WT6%_'0FKJW_37+Y'N9`]Y%Y:Y
MEURNX5)=?&,,E*1A:(I2I2R&M#A\YB#0II8]B+('$I5RORH`E\!1$?M<PZ,Q
M+1A5X(!'T2Y`>.AW;PDI&M^EO"WQK,JP<16<3GR5_6I8+5KC;M)O>UKWO[;>
MRKMN8NLS3BE.*4XI4!\^/A]/Y?3^CBJ$GPK'%V@TNQU?=F%;G=BU?&LO-A[J
MQ0LMFE`):_Y@TX+>]8K14@\-0;J`K-*\D@JFT$S0IO7ZO7]KSS#3GW&I*4*<
M6U'[)5=*0JZ@H"VJ5>'NKYY^YW)<AC.:M8V9F<GAN/'#+=;<B10_W98?"0A1
M,:0+ALW"/1?K5*[#L5M3NE;C]&W[>LNICCK)D5LJTW`Y`BRE;SHLX_NR=U<V
MR+0SK0$H&?08Q\2=>+*L@1F9P(!Y`WPBJEO%22X^XVV6$%-D`E:B%;B;H-K>
MG33K6JY+EV5;S3$?/<AS>,Q2N.09#"VX`2J3)<+P?+R#%D]MX!#14P%(""NP
M%C5-[+KG<I[4<HG&2.U2RK7J&QTK0(^B-:A2[&YO2MU<0ZDR]86G.+/^+2+2
MO@1TX@V"31X9`AE$DCG$J9O!V9DU,M.M]TH^DWJVI2#O)`'S)(T%[@6-:WEN
M6_>5S"XC(1QF'7$\3$R6F*F,RZ97U`1W%I?CN;BELA:HS00O;<A)(M4_RLKW
M7T&QPM;S^[SKQRRZHY19G-G@9JLT*F2&NV5>YLIJ?7/;<DL[N?;&<Q355Q&H
MDC%&R0?:3(*P`'HI>96\6V"3:*@W](!<-[D[D$^1L"*S$F=][L]DHV.P$Q]:
MT\:A/*=:4Q&85->[@==/U$-9<2%)25,I[92/`;K5Y^G:SJM7LNZ0&C[]KV>W
M*C9]0_Z3PF<9H28J-_MI\>82ECD4'_\`2FUA))2>I"NW]`NFH)D$$@(0`\A2
M1+E,K?0Z\XAUMM)0$H"@HE&IN4*ZKN+7%@.@JSDW+N4XO(YJ!R+/Y3&YB#CX
MQ@M18B7&93_T6YU6XPG]X<F`HMW$6!L`GK4J:_JO<]-6Q3-=5UIJS@.O_7N9
M<KU=.J0<34='T"!F_P";K3:*S,YK;K%<(&!GFS=:98Q!RNHYJ4X`C]KU$LDR
M<Q92V]X"66R2`C:E:AZK@I*E`'YMO3H-:P_+^5?>M#K\S&'*AIG`8IP]A,9#
M;$V4VOZAU]IUAQYYIMP)4\VP=S:`0$CK58+EV2[$Q6M0-F@:3H5DP'+UJG1]
M5F:Y38I:N7E[/1Y2:;HD6H_<M+U\C,Y)]&J1B<;'KM7Z99$%!'T)^F2_/GHE
M@H;68+>U)(3\U]"H$ZC:;6'0B_E6X9G[D_<./R]C(X^%D)'`<=V(TUQJ,DMR
M%.I`E2D;K2`(BE-EI+;92X.[N^4"I^K4;M<5K/9%!UM>QV2JY91:W8<Y83,3
M2PA[/+VZB6V3?MUW4?1(]S-!`S#1J9LDV6(=(Y2D6^9ZA`TIE,T2GPIUQ332
M4[4E*+**DJ\0`="!^%;+BXO-6.6\A#V:R\G$XV$R]$0XU&#3RWX[RU)4I$9"
ME]IQ*-J4%)!L%WO8T64V?03RN8MMDW#:<=AI+J;B]T1?4K-0DCVG6K`G-FT(
MDXN7,+E]SDV'W=F)F/AF5O\`-^!`\\@)F2]Z1-=6R3&;5H@$%9'JN=BO&VFG
M72M"<YIR;Z^`QR[-Y?#0G.+09"5L0TK+\]U),H.$Q)&U2%6':L@`$V%A7JT3
M8>Z+A+`K1'Q#R_(M^L+2_P"P9K8JTE5)_0)E>\GAW*M3FU&$:SKNH,J^4CMM
M%NODLY`AC)G*@8R:I:L2\JH,/(NH=@+<04V*B56])T"5#KM.A%3\+R[[SN(P
MF6BL*GLIXV),^(ZT&7)3BI2FSV'=B0U+2RGN(95M0X+@I02#5\/4RWW6_=>L
MWN6ADG$KA8&,T_ET++#A7Y]L`VB;2CFDM"@W:A'/6D2D@F=/T!X$OGR;SZAR
M^,=D/P4.R@H/JO<$;3\QM<>&EJ[?]JLOFL]P''YCD*749A]+JEI=1VW$CONA
MM*VP$[5);"`1;J+ZWO5Q?)U="IQ2G%*<4IQ2G%*<4IQ2G%*@/T<>(]]45\IK
MB3_/^^/[`Y4]![JN/0>[\S7(/K_M'E@ZGW_D*M'3^/.NO_Q0_9ROE\?SIY_#
M\JY?4/[QOVCR@\/>?Q-!X>_\Z)_X?[S?\0\J.E41\M/K+^\?_5RQ/7XJ_&JU
M$?\`$'Y?4/+O[_@/SJIZ#WUU#]"?[_\`J'EPZ#W#\J\O^WWUVE_S?O#^P.4'
B4^_\A7J.G\_Q-<1_UARIJI\*[.*MIQ5:<4IQ2G%*<4K_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
